Dr. Odunsi and his colleagues observed that the tumors of some patients were full of T cells that had managed to work their way inside the tumor. When there were many of these T cells, the patients tended to live longer.
A combination of two immunotherapy drugs shows promise in treating patients with skin cancer that has spread to the brain, according to a study published this week the New England Journal of Medicine. Results of a clinical trial in 94 patients from 28 centers across the United States, in
Not all patients respond to all types of immunotherapies. So how can doctors identify which treatments have the best chance of working in a specific patient? How can they quickly zero in on the best options on a list of immunotherapies that grows longer every day?
Roswell Park Comprehensive Cancer Center researchers have made another step toward personalizing cancer treatment while reducing the toxicity of certain cancer drugs using simple, noninvasive blood tests.
Results from the CheckMate 214 clinical trial show that combined therapy with two immunotherapy drugs, nivolumab and ipilimumab, can be very effective in the treatment of renal cell carcinoma, the most common type of kidney cancer.
A new clinical trial open at Roswell Park Comprehensive Cancer Center is currently investigating whether beta blockers, which calm the body’s response to stress, can boost immunotherapy in patients with advanced melanoma.